Abstract
Comprehensive Forecasts for Neurodegenerative Conditions
The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:
- Sales among all drugs profiled in this report total $18.5 billion and are
expected to increase 62% to $29.7 billion by 2012.
- The majority of this growth is projected to be in multiple sclerosis,
which will increase from a $12.6 billion market to upwards of $20 billion in
2012.
Neurodegenerative disease patients have few treatment options, which often
provide only limited effectiveness. Companies that can invest in and develop
new, tolerable therapies which improve patients' quality of life could see
hundreds of millions - or even billions - of dollars in sales.
In one convenient, easy-to-access format, Neurodegenerative Market Forecast to
2013 provides a compelling, full picture of the Alzheimer' s, Multiple
Sclerosis and Parkinson' s markets.
Detailed Product Profiles
CEI' s veteran analysts examine 40 brands representing different classes and
stages of development. The profiled products represent over 90% of sales in
the neurodegenerative market. Each drug profile has the following components:
- Drug history
- Competitive and strategic positioning:
- Current status of drug
- Sales position within its class
- Presence or strength of competition
- Market growth opportunities:
- Analysis combines new/current sales or clinical trial info with
projections, predictions, insights
- Analysis supported by sales projection charts, covering up to the next 7
years
- Materiality charts, for 2007 and 2012
- Charts containing market exclusivity and patent information for approved
drugs
- Clinical trial data tables to quickly show clinical detail:
- Describes trial and why drug is in its current stage
- Progress of drug
| 
View Cart
